Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: The ADVANCE trial

Diabetes Care

Volumn 40, Issue 9, 2017, Pages 1203-1209

  Ohkuma, Toshiaki ^a   Jun, Min ^a   Woodward, Mark ^a,b,c   Zoungas, Sophia ^a,d   Cooper, Mark E ^e   Grobbee, Diederick E ^f   Hamet, Pavel ^g   Mancia, Giuseppe ^h   Williams, Bryan ⁱ   Welsh, Paul ^j   Sattar, Naveed ^j   Shaw, Jonathan E ^e   Rahimi, Kazem ^b   Chalmers, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TRIACYLGLYCEROL; TROPONIN T;

AGED; BLOOD; COHORT ANALYSIS; COMPLICATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SAMPLE SIZE;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HEART FAILURE; HUMANS; INCIDENCE; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; SAMPLE SIZE; TRIGLYCERIDES; TROPONIN T;

EID: 85028081661     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0509     Document Type: Article

References (28)

1. Yancy CW, Jessup M, Bozkurt B, et al.; Writing Committee Members; American College of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines. 2013ACCF/AHAguideline for themanagement of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-e327
2. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1z9 million people. Lancet Diabetes Endocrinol 2015;3:105-113
3. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75
4. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-851
5. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140
6. Danesh J, Kaptoge S, Mann AG, et al. Longterm interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoSMed 2008;5:e78
7. Wannamethee SG, Welsh P, Lowe GD, et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011;58:56-64
8. Welsh P, Doolin O, Willeit P, et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J 2013; 34:443-450
9. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-1604
10. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and Diamicron MR controlled evaluation. Diabetologia 2001;44: 1118-1120
11. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular andmicrovascular outcomes in patientswith type 2 diabetesmellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840
12. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2diabetes.NEngl JMed 2008;358:2560-2572
13. Levey AS, Stevens LA, Schmid CH, et al.; CKDEPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann InternMed 2009;150:604-612
14. Woodward M. Epidemiology: Study Design and Data Analysis. Boca Raton, Chapman and Hall/CRC, 2014
15. Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2014;63: 1115-1123
16. Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 2014;37:295-303
17. Welsh P, Woodward M, Hillis GS, et al. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results fromthe ADVANCE trial. Diabetes Care 2014;37:2202-2210
18. Newson R. Comparing the predictive power of survival models using Harrell's C or Somers' D. Stata J 2010;10:339-358
19. Echouffo-Tcheugui JB, Greene SJ, PapadimitriouL, et al. Population risk prediction models for incident heart failure: a systematic review. Circ Heart Fail 2015;8:438-447
20. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart Fail 2014;2: 440-446
21. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48: 156-163
22. Scirica BM, Braunwald E, Raz I, et al.; SAVORTIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-1588
23. Barac A,Wang H, Shara NM, et al.Markers of inflammation,metabolic risk factors, and incident heart failure inAmerican Indians: the StrongHeart Study. J Clin Hypertens (Greenwich) 2012;14:13-19
24. Zinman B,Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
25. Fitchett D, Zinman B, Wanner C, et al.; EMPAREG OUTCOME- trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME- trial. Eur Heart J 2016;37:1526-1534
26. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 2016;59:1333-1339
27. Ghashghaei R, Arbit B,Maisel AS. Current and novel biomarkers in heart failure: bench to bedside. Curr Opin Cardiol 2016;31:191-195
28. Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 2010;55:340-347